Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018

  • ID: 4496235
  • Report
  • 159 Pages
  • GBI Research
1 of 5

FEATURED COMPANIES

  • AdAlta Ltd
  • Boehringer Ingelheim GmbH
  • DURECT Corp
  • GlaxoSmithKline Plc
  • Novartis AG
  • Saje Pharma LLC
  • MORE

Summary

Both NASH and NAFLD occur largely as a result of prolonged insulin resistance and obesity with approximately 80% of cases being diagnosed in overweight individuals. NASH is a severe form of NAFLD and is likely to become even more of a healthcare burden than it is at present. NASH can lead to liver cirrhosis and ultimately liver failure, which can be fatal if it is not treated quickly.

There are a total of 195 pipeline products in development for NASH and 65 products in development for NAFLD. Across the therapy area there are 158 companies developing products for NASH and 57 companies developing products for NAFLD. Key companies active in this space include Gilead, Novartis and Pfizer.

This report “Non Alcoholic Fatty Liver Disease (NAFLD) and NonAlcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018” provides an overview of the pipeline for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The report provides comprehensive information on the therapeutics under development and key players active in this space, and features dormant and discontinued projects.

Scope

  • Which companies are the most active within the pipeline for NAFLD and NASH therapeutics?
  • Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

  • Understand the overall pipeline, with an ataglance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an uptodate overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AdAlta Ltd
  • Boehringer Ingelheim GmbH
  • DURECT Corp
  • GlaxoSmithKline Plc
  • Novartis AG
  • Saje Pharma LLC
  • MORE

1 Introduction
1.1 Gastrointestinal Report Coverage
1.2 Non-Alcoholic Steatohepatitis (NASH) - Overview
1.3 Non Alcoholic Fatty Liver Disease (NAFLD) - Overview

2 Therapeutics Development
2.1 Non-Alcoholic Steatohepatitis (NASH)
2.2 Non Alcoholic Fatty Liver Disease (NAFLD)

3 Therapeutics Assessment
3.1 Non-Alcoholic Steatohepatitis (NASH)
3.2 Non Alcoholic Fatty Liver Disease (NAFLD)

4 Companies Involved in Therapeutics Development
4.1 Non-Alcoholic Steatohepatitis (NASH)
4.2 Non Alcoholic Fatty Liver Disease (NAFLD)

5 Dormant Projects
5.1 Non-Alcoholic Steatohepatitis (NASH)
5.2 Non Alcoholic Fatty Liver Disease (NAFLD)

6 Discontinued Products
6.1 Non-Alcoholic Steatohepatitis (NASH)
6.2 Non Alcoholic Fatty Liver Disease (NAFLD)

7 Product Development Milestones
7.1 Non-Alcoholic Steatohepatitis (NASH)
7.2 Non Alcoholic Fatty Liver Disease (NAFLD)

8 Appendix
8.1 Methodology
8.2 Coverage
8.3 Secondary Research
8.4 Primary Research
8.5 Expert Panel Validation
8.6 Contact
8.7 Disclaimer

List of Tables
Table 1: Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH)
Table 2: Number of Products under Development by Companies, Non-Alcoholic Steatohepatitis (NASH)
Table 3: Number of Products under Development by Universities/Institutes, Non-Alcoholic Steatohepatitis (NASH)
Table 4: Products under Development by Companies, Non-Alcoholic Steatohepatitis (NASH)
Table 5: Products under Development by Universities/Institutes, Non-Alcoholic Steatohepatitis (NASH)
Table 6: Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD)
Table 7: Number of Products under Development by Companies, Non Alcoholic Fatty Liver Disease (NAFLD).
Table 8: Number of Products under Development by Universities/Institutes, Non Alcoholic Fatty Liver Disease (NAFLD).
Table 9: Products under Development by Companies, Non Alcoholic Fatty Liver Disease (NAFLD).
Table 10: Products under Development by Universities/Institutes, Non Alcoholic Fatty Liver Disease (NAFLD).
Table 11: Number of Products by Stage and Target, Non-Alcoholic Steatohepatitis (NASH)
Table 12: Number of Products by Stage and Mechanism of Action, Non-Alcoholic Steatohepatitis (NASH)
Table 13: Number of Products by Stage and Route of Administration, Non-Alcoholic Steatohepatitis (NASH)
Table 14: Number of Products by Stage and Molecule Type, Non-Alcoholic Steatohepatitis (NASH)
Table 15: Number of Products by Stage and Target, Non Alcoholic Fatty Liver Disease (NAFLD)
Table 16: Number of Products by Stage and Mechanism of Action, Non Alcoholic Fatty Liver Disease (NAFLD)
Table 17: Number of Products by Stage and Route of Administration, Non Alcoholic Fatty Liver Disease (NAFLD)
Table 18: Number of Products by Stage and Molecule Type, Non Alcoholic Fatty Liver Disease (NAFLD)
Table 19: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by AdAlta Ltd
Table 20: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Albireo Pharma Inc
Table 21: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Allergan Plc
Table 22: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Amunix Operating Inc
Table 23: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Aquinox Pharmaceuticals Inc
Table 24: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Arcturus Therapeutics Ltd
Table 25: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Ardelyx Inc
Table 26: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Arisaph Pharmaceuticals Inc
Table 27: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Assembly Biosciences Inc
Table 28: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by AstraZeneca Plc
Table 29: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by BASF SE
Table 30: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Betagenon AB
Table 31: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Bird Rock Bio Inc
Table 32: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by BLR Bio LLC
Table 33: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Boehringer Ingelheim GmbH
Table 34: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Bristol-Myers Squibb Co
Table 35: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Cadila Healthcare Ltd
Table 36: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Can-Fite BioPharma Ltd
Table 37: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Cardax Inc
Table 38: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Carmot Therapeutics Inc
Table 39: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Catabasis Pharmaceuticals Inc
Table 40: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Cerenis Therapeutics Holding SA
Table 41: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ChemoCentryx Inc
Table 42: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by CohBar Inc
Table 43: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Connexios Life Sciences Pvt Ltd
Table 44: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ConSynance Therapeutics Inc
Table 45: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by CymaBay Therapeutics Inc
Table 46: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Daiichi Sankyo Co Ltd
Table 47: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Debiopharm International SA
Table 48: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Dicerna Pharmaceuticals Inc
Table 49: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Dimerix Bioscience Pty Ltd
Table 50: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Dong-A Socio Holdings Co Ltd
Table 51: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by DURECT Corp
Table 52: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Eli Lilly and Co
Table 53: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Enanta Pharmaceuticals Inc
Table 54: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Enyo Pharma SA
Table 55: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Exicure Inc
Table 56: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Forma Therapeutics Inc
Table 57: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Galectin Therapeutics Inc
Table 58: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Galecto Biotech AB
Table 59: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Galmed Pharmaceuticals Ltd
Table 60: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Gemphire Therapeutics Inc
Table 61: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Genfit SA
Table 62: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by GenKyoTex SA
Table 63: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Gilead Sciences Inc
Table 64: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by GlaxoSmithKline Plc
Table 65: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by GRI Bio Inc
Table 66: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd
Table 67: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Hanmi Pharmaceuticals Co Ltd
Table 68: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by HemoShear Therapeutics, LLC
Table 69: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by iCo Therapeutics Inc.
Table 70: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Immuron Ltd
Table 71: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Intercept Pharmaceuticals Inc
Table 72: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Inventiva
Table 73: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Ionis Pharmaceuticals Inc
Table 74: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Kissei Pharmaceutical Co Ltd
Table 75: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Kyorin Pharmaceutical Co Ltd
Table 76: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Madrigal Pharmaceuticals Inc.
Table 77: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Matinas BioPharma Holdings Inc
Table 78: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by MedImmune LLC
Table 79: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Merck & Co Inc
Table 80: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Metacrine Inc
Table 81: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Mitsubishi Tanabe Pharma Corp
Table 82: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Naia Ltd
Table 83: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by NeuroVive Pharmaceutical AB
Table 84: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by NGM Biopharmaceuticals Inc
Table 85: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Nippon Chemiphar Co Ltd
Table 86: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Novartis AG
Table 87: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by NovaTarg Therapeutics Inc
Table 88: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Novo Nordisk AS
Table 89: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Nuevolution AB
Table 90: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Ocera Therapeutics Inc
Table 91: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Oramed Pharmaceuticals Inc
Table 92: Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Pfizer Inc

List of Figures
Figure 1: Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH)
Figure 2: Number of Products under Development by Companies, Non-Alcoholic Steatohepatitis (NASH)
Figure 3: Number of Products under Development by Universities/Institutes, Non-Alcoholic Steatohepatitis (NASH)
Figure 4: Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD)
Figure 5: Number of Products under Development by Companies, Non Alcoholic Fatty Liver Disease (NAFLD).
Figure 6: Number of Products by Top 10 Targets, Non-Alcoholic Steatohepatitis (NASH)
Figure 7: Number of Products by Stage and Top 10 Targets, Non-Alcoholic Steatohepatitis (NASH)
Figure 8: Number of Products by Top 10 Mechanism of Actions, Non-Alcoholic Steatohepatitis (NASH)
Figure 9: Number of Products by Stage and Top 10 Mechanism of Actions, Non-Alcoholic Steatohepatitis (NASH)
Figure 10: Number of Products by Routes of Administration, Non-Alcoholic Steatohepatitis (NASH)
Figure 11: Number of Products by Stage and Routes of Administration, Non-Alcoholic Steatohepatitis (NASH)
Figure 12: Number of Products by Top 10 Molecule Types, Non-Alcoholic Steatohepatitis (NASH)
Figure 13: Number of Products by Stage and Top 10 Molecule Types, Non-Alcoholic Steatohepatitis (NASH)
Figure 14: Number of Products by Top 10 Targets, Non Alcoholic Fatty Liver Disease (NAFLD)
Figure 15: Number of Products by Stage and Top 10 Targets, Non Alcoholic Fatty Liver Disease (NAFLD)
Figure 16: Number of Products by Top 10 Mechanism of Actions, Non Alcoholic Fatty Liver Disease (NAFLD)
Figure 17: Number of Products by Stage and Top 10 Mechanism of Actions, Non Alcoholic Fatty Liver Disease (NAFLD)
Figure 18: Number of Products by Routes of Administration, Non Alcoholic Fatty Liver Disease (NAFLD)
Figure 19: Number of Products by Stage and Routes of Administration, Non Alcoholic Fatty Liver Disease (NAFLD)
Figure 20: Number of Products by Top 10 Molecule Types, Non Alcoholic Fatty Liver Disease (NAFLD)
Figure 21: Number of Products by Stage and Top 10 Molecule Types, Non Alcoholic Fatty Liver Disease (NAFLD)

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AdAlta Ltd
  • Akcea Therapeutics Inc
  • Albireo Pharma Inc
  • Allergan Plc
  • Amunix Operating Inc
  • Aquinox Pharmaceuticals Inc
  • Arcturus Therapeutics Ltd
  • Ardelyx Inc
  • Arisaph Pharmaceuticals Inc
  • Assembly Biosciences Inc
  • AstraZeneca Plc
  • BASF SE
  • Betagenon AB
  • Bird Rock Bio Inc
  • BLR Bio LLC
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Cadila Healthcare Ltd
  • Can-Fite BioPharma Ltd
  • Cardax Inc
  • Carmot Therapeutics Inc
  • Catabasis Pharmaceuticals Inc
  • Cerenis Therapeutics Holding SA
  • ChemoCentryx Inc
  • CJ HealthCare Corp
  • CohBar Inc
  • Connexios Life Sciences Pvt Ltd
  • ConSynance Therapeutics Inc
  • Corcept Therapeutics Inc
  • CymaBay Therapeutics Inc
  • Daewoong Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • Debiopharm International SA
  • Dicerna Pharmaceuticals Inc
  • Dimerix Bioscience Pty Ltd
  • Dong-A Socio Holdings Co Ltd
  • Dr. Falk Pharma GmbH
  • DURECT Corp
  • Eli Lilly and Co
  • Enanta Pharmaceuticals Inc
  • Enyo Pharma SA
  • Eternygen GmbH
  • Evgen Pharma Plc
  • Exicure Inc
  • Forma Therapeutics Inc
  • Galectin Therapeutics Inc
  • Galecto Biotech AB
  • Galmed Pharmaceuticals Ltd
  • Gemphire Therapeutics Inc
  • Genfit SA
  • GenKyoTex SA
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • GRI Bio Inc
  • Guangdong Zhongsheng Pharmaceutical Co Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • HemoShear Therapeutics, LLC
  • Huons Global Co Ltd
  • iCo Therapeutics Inc.
  • Immuron Ltd
  • Intercept Pharmaceuticals Inc
  • Inventiva
  • Ionis Pharmaceuticals Inc
  • Kissei Pharmaceutical Co Ltd
  • Kowa Co Ltd
  • Kyorin Pharmaceutical Co Ltd
  • Madrigal Pharmaceuticals Inc.
  • Matinas BioPharma Holdings Inc
  • MedImmune LLC
  • Merck & Co Inc
  • Metacrine Inc
  • Mitsubishi Tanabe Pharma Corp
  • Miyarisan Pharmaceutical Company Ltd
  • Naia Ltd
  • NeuroVive Pharmaceutical AB
  • NGM Biopharmaceuticals Inc
  • Nippon Chemiphar Co Ltd
  • Novartis AG
  • NovaTarg Therapeutics Inc
  • Novo Nordisk AS
  • Nuevolution AB
  • Ocera Therapeutics Inc
  • Oramed Pharmaceuticals Inc
  • Pfizer Inc
  • Pharmaxis Ltd
  • Phenex Pharmaceuticals AG
  • Promethera Biosciences SA
  • ProMetic Life Sciences Inc
  • Protalix BioTherapeutics Inc
  • Redx Pharma Plc
  • Regulus Therapeutics Inc
  • reMYND NV
  • Renova Therapeutics Inc
  • Ritter Pharmaceuticals Inc
  • Saje Pharma LLC
  • Sancilio & Company Inc
  • Sanofi
  • Second Genome Inc
  • Seres Therapeutics Inc
  • Shenzhen HighTide Biopharmaceutical Ltd
  • Shire Plc
  • Sprint Bioscience AB
  • Synlogic Inc
  • TaiwanJ Pharmaceuticals Co Ltd
  • TCM Biotech International Corp
  • Theratechnologies Inc
  • Tiziana Life Sciences Plc
  • TRACON Pharmaceuticals Inc
  • Translate Bio Inc
  • Vascular Biogenics Ltd
  • Verlyx Pharma Inc
  • Viking Therapeutics Inc
  • Zebra Discovery Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll